CYAD Key Statistics, Chart & Performance
The current stock price of CYAD is 0.47 USD. In the past month the price decreased by -27.27%. In the past year, price decreased by -76.5%.
CYAD Technical Analysis
CYAD Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CYAD. CYAD may be in some trouble as it scores bad on both profitability and health.
CYAD Financial Highlights
Over the last trailing twelve months CYAD reported a non-GAAP Earnings per Share(EPS) of -1.95. The EPS decreased by -5.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.03 |
CYAD Forecast & Estimates
10 analysts have analysed CYAD and the average price target is 0.48 USD. This implies a price increase of 1.41% is expected in the next year compared to the current price of 0.47.
CYAD Ownership
CYAD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.37 | 394.886B | ||
| AMGN | AMGEN INC | 16.68 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.01 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.1 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.8 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.77 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 12.74 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.62 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CYAD
Company Profile
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 28 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
Company Info
Celyad Oncology SA
Axis Business Park Rue Edouard Belin 2
Mont-Saint-Guibert BRABANT-WALLON 1435 BE
CEO: Filippo Petti
Employees: 28
Phone: 3210394100.0
Celyad Oncology SA / CYAD FAQ
What does Celyad Oncology SA do?
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 28 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
What is the current price of CYAD stock?
The current stock price of CYAD is 0.47 USD. The price decreased by -11.1% in the last trading session.
Does CYAD stock pay dividends?
CYAD does not pay a dividend.
How is the ChartMill rating for Celyad Oncology SA?
CYAD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of Celyad Oncology SA (CYAD)?
Celyad Oncology SA (CYAD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.95).
Who owns Celyad Oncology SA?
You can find the ownership structure of Celyad Oncology SA (CYAD) on the Ownership tab.